Aptose Biosciences Inc. (APTO)
| Market Cap | 20.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -49.25M |
| Shares Out | 7.94M |
| EPS (ttm) | -7.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 72,512 |
| Open | 2.48 |
| Previous Close | 2.45 |
| Day's Range | 2.43 - 2.57 |
| 52-Week Range | 0.36 - 6.60 |
| Beta | 1.38 |
| Analysts | Strong Buy |
| Price Target | 37.67 (+1,383.07%) |
| Earnings Date | Nov 9, 2023 |
About APTO
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed o... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for APTO stock is "Strong Buy." The 12-month stock price forecast is $37.67, which is an increase of 1,383.07% from the latest price.
News
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
Reporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML Patients TUS Single Agent and TUS/VEN Combination Demonstrate Fa...
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly dif...
Aptose Reports Results for the Third Quarter 2023
Aptose Reports Results for the Third Quarter 2023 • TUS/VEN Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
SAN DIEGO and TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly dif...
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
Tusp etinib (TUS) Combination with Venetoclax (VEN) Clinical Findings Highlighted TUS Targets VEN Resistance Mechanisms to Re-sensitize VEN Failure Patients to VEN 44% ORR with TUS/VEN in Difficult-...
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
SAN DIEGO and TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted ag...
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
SAN DIEGO and TORONTO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly dif...
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
Aptose to present TUS/VEN AML data at ESH; to hold clinical update webcast on October 30th. TUS appears to re-sensitize Prior-VEN failure patients to VEN.
Aptose to Present at the Cantor Global Healthcare Conference
SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly di...
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
— TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax — — TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax —
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly dif...
Aptose Reports Results for the Second Quarter 2023
─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
SAN DIEGO and TORONTO, July 27, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted ag...
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
SAN DIEGO and TORONTO, June 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly dif...
Aptose Presents Highlights from Clinical Update
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML Patients Favorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat R...
Aptose Biosciences Provides Update on Reverse Stock Split
SAN DIEGO and TORONTO, June 05, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly dif...
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
SAN DIEGO and TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly diff...
Aptose Enters into $25 Million Committed Equity Facility
SAN DIEGO and TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly diff...
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
SAN DIEGO and TORONTO, May 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly diff...
Aptose Reports Results for the First Quarter 2023
─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
SAN DIEGO and TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted ag...
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted ...
Aptose to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly di...
Aptose Biosciences to Participate in Cantor's The Future of Oncology Virtual Symposium
SAN DIEGO and TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inh...
Aptose Reports Results for the Fourth Quarter and Full Year 2022
─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─